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Abstract
Aims
2 dimensional (2D) strain analysis detects subclinical left ventricular (LV) systolic dysfunc-
tion. Our aim was to evaluate changes in LV systolic and diastolic function in breast cancer
patients early after anthracycline chemotherapy, and to identify predisposing factors.
Methods and results
140 patients were assessed by detailed echocardiography before and within seven days
post treatment. LV ejection fraction (LVEF), global longitudinal strain (GLS), strain rate and
radial and circumferential strain were assessed. Additionally, left atrial volumes and LV dia-
stolic parameters were evaluated. LVEF although reduced after treatment, remained within
the normal range (603% vs. 593%, p = 0.04). Triplane GLS was significantly reduced
after treatment (-20.01.6% vs. -19.11.8%, p0.001). Subclinical LV dysfunction (!11%
reduction in GLS compared to before therapy) occurred in 22% (29/135). Impaired diastolic
function grade significantly increased from 46% to 57% (p0.001) after treatment. Further-
more, diastolic dysfunction was more common in the subgroup group with reduced systolic
GLS compared to those without changes in GLS (30% vs. 11%; p = 0.04). No risk factors or
clinical parameters were associated with the development of subclinical LV dysfunction;
however the percentage change in early diastolic strain rate and the E velocity were inde-
pendent predictors of !11% reduction in GLS.
Conclusion
Twenty two percent of patients had subclinical LV dysfunction by GLS, whilst none had cardi-
otoxicity defined by LVEF, demonstrating that GLS is more sensitive for detection of subclini-
cal LV systolic dysfunction immediately after anthracycline therapy. Diastolic dysfunction
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increased, particularly in the group with reduced GLS, demonstrating the close pathophysio-
logical relationship between systolic and diastolic function.
Introduction
Anthracyclines are the cornerstone in breast cancer chemotherapy [1] with doxorubicin and
epirubicin most frequently used [2]. They possess potent antitumour properties, a major factor
in improved breast cancer survival [3]. However, anthracyclines are potentially cardiotoxic
with cardiac dysfunction characterised by permanent and dose dependent myocardial damage
[4]. The incidence of congestive heart failure or cardiac death in breast cancer patients receiv-
ing chemotherapy was 3% by 3 years compared to 1% in an age matched cohort not receiving
chemotherapy [5]. The overall incidence of cardiotoxicity, defined as a reduction in left ven-
tricular ejection fraction (LVEF), has been reported in up to 9% of patients receiving anthracy-
clines [6]. Furthermore, almost one third of patients receiving anthracyclines, trastuzumab or
both, developed abnormal global longitudinal strain (GLS) at 6 months [7]. For this reason,
breast cancer patients treated with anthracyclines require close evaluation of cardiac function
after chemotherapy to enable early identification and treatment of cardiotoxicity [8, 9].
Echocardiography is the foundation for monitoring cardiotoxicity [10]. Historically, LVEF
has been the key parameter for detecting cardiotoxicity; however, small changes in LVEF have
low sensitivity given the variability in LVEF measurements [10]. More recently, 2D myocardial
strain imaging has been shown to be more sensitive than LVEF in detecting LV systolic dys-
function following anthracyclines [10,11, 12].
While early changes in systolic function have been described, only limited studies with
small sample sizes have assessed the effect of anthracycline chemotherapy on LV diastolic
function, and particularly the relationship between systolic and diastolic function in this set-
ting. Diastolic dysfunction may precede systolic dysfunction providing an early marker of car-
diotoxicity and development of heart failure with relatively preserved systolic function.
We evaluated LV systolic and diastolic function in a large single centre cohort of chemo-
therapy naïve breast cancer patients before anthracycline treatment and within seven days
after treatment, to evaluate myocardial dysfunction in a larger cohort than previously pub-
lished reports. The main aim of this study was to evaluate and characterise the cardiotoxic
effects of anthracyclines by the use of strain analysis and traditional echocardiographic mea-
sures. We also sought to examine segmental LV function and to identify clinical and echocar-
diographic predictors for the development of subclinical LV dysfunction.
Methods
Study approval was obtained from the Committees for Human Research at SydneyWest Area
Health Service and the University of Sydney; all subjects provided written informed consent. 151
consecutive patients with histologically confirmed breast cancer were prospectively recruited.
Anthracycline chemotherapy, either doxorubicin or epirubicin, was administered (4 to 6 cycles)
as determined by the treating oncologist. No patients were receiving trastuzumab therapy at the
time of this study. 35 patients went on to be treated with trastuzumab after the conclusion of this
study. All patients underwent detailed clinical evaluation including cardiovascular history and
risk factors (hypertension, diabetes, cholesterol, smoking history), cardioactive medications,
family history, height, weight and blood pressure. Blood tests (haemoglobin, eGFR, creatinine)
were performed before and after completion of anthracycline chemotherapy. Exclusion criteria
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included previous chemotherapy or radiation treatment, coronary artery disease, more than
mild valvular disease, history of atrial or ventricular arrhythmias, an LVEF<50%, previous car-
diac surgery or implanted devices.
All participants underwent a comprehensive transthoracic echocardiogram, according to
established laboratory practice (Vivid 7 General Electric medical systems, Norway). Optimised
imaging of the left ventricle (LV) was performed and all measurements were averaged over
three consecutive cardiac cycles and offline analysis was performed using Echopac PC 6.1.0.
(General Electric Vingmed, Norway). Baseline echocardiograms were performed at least one
week prior to the commencement of anthracycline chemotherapy. Follow-up echocardio-
grams were performed within 7 days of completion of anthracycline chemotherapy (12 to 18
weeks following the baseline study) and prior to commencement of trastuzumab or thoracic
radiation. Eleven patients were excluded due to inadequate image quality following left breast
surgery; the remaining 140 patients were included in the analysis. All echocardiograms were
performed with the patient in the left lateral position and images were obtained from the para-
sternal, apical and subcostal views.
Left ventricular (LV) systolic function
LV volumes were measured from the apical 4 and 2-chamber views using the modified
Simpson’s biplane method of discs, and LVEF was calculated [13]. Cardiac output was
obtained by multiplying the Doppler calculated stroke volume by heart rate. Anthracycline
related cardiac dysfunction was defined as an asymptomatic reduction in LVEF of >10% to
a value of <53% as per guidelines [10]. LV mass was measured using the 2D linear cube
method from the parasternal long axis view [13]. Pulsed wave Doppler tissue imaging was
used to measure the average peak velocity in systole (S’) with the sample volume placed at
the septal and lateral annulus.
2D strain analysis was used to measure global and regional longitudinal systolic strain from
the apical four, two and three chamber views (basal, mid and apical segments from the septal,
lateral, inferior, anterior, posterior and anteroseptal walls; (Fig 1), obtained at high frame rates
(60-80fps) and optimised for 2D quality. The LV regions of interest were manually selected by
marking the endocardial border. Measurements were only accepted if at least 4/6 segments
from each apical view were adequately tracked. Systolic strain was measured as the peak nega-
tive strain during systole. Global biplane (12 segments from 4- and 2- chamber views) and tri-
plane (18 segments from 4-, 2-, 3- chamber views longitudinal strain (GLS) was calculated as
the average of the regional values. Subclinical cardiac dysfunction was defined as a reduction
in GLS of>11% as previously reported [14]. Global systolic strain rate was calculated from the
triplane apical segments (Fig 2). Global radial and circumferential strain were measured as the
average of the six regional segments from the parasternal short axis view at the level of the pap-
illary muscles (Fig 3).
Left atrial (LA) volumes and diastolic function
LA maximum volume, LA minimal volume and LA pre ‘a’ wave volume (onset of P wave on
ECG) were measured using the biplane area-length method. Phasic LA volumes including pas-
sive, conduit and active volumes and fractions were also calculated [15]. LA reservoir function
occurs during systole and involves the storage of blood within the atria and is measured as the
total emptying volume (LA maximum volume- LA minimal volume/ LA maximum volume).
LA conduit function occurs during early diastole and involves the passive transfer of blood
and is measured as the passive emptying volume (LA maximum volume- LA pre ‘a’ volume).
LA active atrial function occurs during late diastole to augment ventricular filling and is
Anthracyclines induce early changes in ventricular function
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Fig 1. Global longitudinal strain. Peak systolic negative deflection from six segments (basal, mid and
apical) from each view A. Four chamber view–septal and lateral walls; B. Two chamber view–inferior and
anterior walls and C. Long axis view–posterior and anteroseptal walls. X-axis = Time (s); Y-axis = Strain (%).
https://doi.org/10.1371/journal.pone.0175544.g001
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measured as active emptying volume (LA pre ‘a’ volume–LA minimal volume). The LA con-
duit volume is measured as LV stroke volume–LA stroke volume (where LA stroke volume is
LA maximum volume- LA minimal volume).
Transmitral inflow was obtained using pulsed wave Doppler. The peak velocity in early
diastole (E wave velocity) and the peak velocity in late diastole (A wave velocity) and the E/A
ratio were measured. The downward slope of the early diastolic E wave velocity was measured
to obtain the deceleration time [15]. The active atrial emptying fraction was measured as the
ratio of the A wave velocity time integral (VTI) to the total mitral inflow VTI [15]. Pulmonary
vein peak systolic, diastolic and atrial reversal velocities were measured and peak systolic to
peak diastolic velocity ratio obtained. Pulsed wave Doppler tissue imaging was used to measure
the averaged peak velocity in early diastole (E’) and late diastole (A’) from the septal and lateral
annulus. Global early diastolic strain rate (Esr) and late diastolic strain rate (Asr) were calcu-
lated from the 18 triplane segments (Fig 2). The E/E’ and E/Esr ratio were calculated as mea-
sures of LV end diastolic pressure.
LV diastolic dysfunction was stratified into four grades according to the ASE guidelines
based on the E’ velocity, E/E’ ratio, E/A ratio, deceleration time and pulmonary vein flow as
normal, impaired relaxation, pseudo normal filling or restrictive [15]. Normal diastolic func-
tion comprised of an E/A ratio> 1 with deceleration time<240 ms with normal E’ velocity
and normal LA volume. The mildest form of diastolic dysfunction is impaired relaxation and
was present if E/A ratio was< 1 and deceleration time exceed 240 ms. Pseudo normal diastolic
dysfunction was present if E/ A ratio was> 1 and deceleration time was< 240 ms, but with
low E’ velocity and an enlarged LA volume (> 34 mL/m2). The severest form of diastolic dys-
function is restrictive filling and was present if E/A ratio was>2 and / or deceleration time
was< 140 ms [15].
Fig 2. Strain rate. Systolic strain rate (Ssr), early diastolic strain rate (Esr) and late diastolic strain rate (Esr).
X-axis = Time (s); Y-axis = Strain rate (s-1).
https://doi.org/10.1371/journal.pone.0175544.g002
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Statistical analysis
All continuous variables are expressed as a mean ± SD and categorical variables as a percent-
age. Paired t-tests were used to compare parameters before and after anthracycline therapy.
Subgroup analysis was performed using unpaired t-tests. Non-parametric variables were
examined by Chi square analysis. Pearson correlations were used to examine associations
between continuous parameters. Multivariate analysis was performed by logistic regression
backward stepwise likelihood ratio. Inter- and intra-observer variability of LVEF, triplane GLS
and systolic strain rate were assessed on fifteen randomly selected patients by intraclass corre-
lation coefficient. Data were analysed using SPSS version 21 (SPSS Inc, Chicago, Illinois), and
considered significant if p< 0.05.
Fig 3. Radial and circumferential strain. A. Radial strain (peak systolic positive deflection) and B. Circum-
ferential strain (peak systolic negative deflection) from the parasternal short axis view at the level of the
papillary muscles (septal, anteroseptal, anterior, lateral, posterior, inferior segments). X-axis = Time (s);
Y-axis = Strain (%).
https://doi.org/10.1371/journal.pone.0175544.g003
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Results
A total of 140 prospectively recruited patients were included in the final analysis; 99/140 (76%)
received doxorubicin (419 ± 67 mg/m2) and 31/140 (24%) epirubicin (therapeutic equivalent
dose 450± 136 mg/m2). Cardiovascular risk factors and cardioactive medications are listed in
Table 1. Thirty six (26%) patients had more than one cardiac risk factor. No participant
reported symptoms of cardiac failure during the chemotherapy.
Haemoglobin was significantly reduced after anthracycline therapy (p<0.001), whilst esti-
mated glomerular filtration rate (p = 0.53) and creatinine (p = 0.24) remained unchanged
(Table 2).
Follow up echocardiograms were performed 95 ± 18 days following the baseline study,
within 7 days of completion of anthracycline chemotherapy. No patient developed significant
valvular / pericardial disease or heart failure early after anthracycline chemotherapy.
Left ventricular systolic function
Clinical and echocardiographic parameters before and after anthracycline chemotherapy are
listed in Table 2. The LV end systolic volume increased slightly post anthracycline therapy
(p = 0.02), with no change in LV end diastolic volume (p = 0.07). LVEF and biplane GLS were
measured in all patients before and after anthracycline therapy (n = 140), whilst triplane GLS
could only be measured in 135 (96%) patients. Global radial and circumferential strain was
obtained in 133 (95%). LVEF (p = 0.04), biplane GLS (p<0.001), triplane GLS (p<0.001) and
global circumferential strain (p = 0.001) decreased significantly after anthracycline therapy.
Global radial strain, systolic strain rate and S’ velocity were unaltered. Whilst there was a statis-
tically significant reduction in LVEF after anthracycline therapy, no patients developed cardio-
toxicity (i.e. reduction in LVEF>10% to<53%) [10].
Subclinical LV dysfunction, defined as>11% reduction in triplane GLS, occurred in 29
patients (22%). Subclinical LV dysfunction was not associated with any cardiovascular risk fac-
tors (family history, hypercholesterolaemia, smoking, hypertension, diabetes), clinical charac-
teristics (age, heart rate, mean arterial blood pressure, body surface area), type of anthracycline
therapy or dose. The incidence of subclinical LV dysfunction by GLS did not correlate with the
percentage change in LVEF (p = 0.05). In the sub group with>11% reduction in GLS, there
was no significant difference in LV end diastolic volume (p = 0.98) or LV end systolic volume
(p = 0.37) compared to before treatment. The incidence of subclinical LV dysfunction was not
associated with the percentage change in global circumferential (p = 0.39) or radial strain
(p = 0.57).
Table 1. Patient cardiovascular risk factors.
Age (years) 52  9 (range 33–77)
Cardiovascular Risk factors Family history 45 (32%)
Hypercholesterolaemia 26 (19%)
Hypertension 31 (22%)
Diabetes 8 (6%)
Smoking 36 (26%)
Cardioactive medications Beta blockers 2 (1%)
Angiotensin converting enzyme inhibitors 7 (5%)
Statins 13 (9%)
Angiotensin II receptor blocker 18 (13%)
Calcium channel blocker 10 (7%)
Diuretics 3 (2%)
https://doi.org/10.1371/journal.pone.0175544.t001
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Nine patients were receiving either an angiotensin converting enzyme inhibitor (perindo-
pril, ramipril, and lisinopril) or a beta blocker (atenolol, propranolol) prior to chemotherapy.
There were no significant differences in LVEF, GLS, radial or circumferential strain before or
after anthracyclines between this group and those not receiving these medications.
Patients receiving doxorubicin had similar LVEF compared to epirubicin after therapy
(59 ± 2% vs. 60 ± 2%, p = 0.23). Additionally there was no significant difference in triplane
GLS (-19.1 ± 1.6% vs. -19.1 ± 2.2%, p = 0.96) after therapy between the drug types. 21% (21/
102) in the doxorubicin group and 24% (8/33) in the epirubicin group had subclinical LV dys-
function by triplane GLS (p = 0.63).
In the group with subclinical LV dysfunction by GLS all 18 regional segments had signifi-
cantly reduced strain after therapy (Fig 4A), while up to five regional segments had reduced
strain after compared to before therapy in the group without reduced GLS (Fig 4B). Further-
more, in the group with subclinical LV dysfunction 9 ± 2 (58 ± 17%) regional segments had a
reduction in strain by>11%, compared to 5 ± 2 (29 ± 15%) regional segments in the group
without dysfunction (p<0.001).
The intra and inter-observer intraclass coefficients for LVEF were 0.77 and 0.84, for triplane
GLS were 0.95 and 0.86, for systolic strain rate were 0.83 and 0.70,
Left atrial (LA) volumes and diastolic function
LA volumes did not change post anthracycline therapy (Table 3). However, 32% of patients
did have a10% increase in LA maximum volume after therapy, whilst 36% had a10%
increase in LA minimum volume. An increase in LA maximum or minimum volume was not
associated with subclinical LV dysfunction (p = 0.18 and p = 0.38).
Table 2. Patient clinical and left ventricular systolic echocardiographic parameters.
Before anthracycline chemotherapy After anthracycline chemotherapy
Haemoglobin (g/L) 131  12 117  12 *
eGFR (mL/min/1.73m2) 84  9 85  11
Creatinine (umol/L) 62  10 61  15
BSA (m2) 1.8  0.2 1.8  0.2
Heart rate (bpm) 71  11 78  11 *
MAP (mmHg) 90  10 90 10
LV mass (g/m2) 75  17 78  16
Cardiac output (L/min) 5.0 1.2 5.2  1.2
LVEDV (mL/m2) 53  9 54  11
LVESV (mL/m2) 21  4 22  5 *
Stroke volume (mL/m2) 30  6 30  6
LVEF (%) 60  3 59  3 *
S’ (cm/s) 8.1  1.4 8.1  1.6
Biplane GLS (%) -20.3  1.7 -19.3  1.8 *
Triplane GLS (%) -20.0  1.6 -19.1  1.8 *
Ssr (s-1) -1.4  0.2 -1.4  0.2
Radial strain (%) 41.5  10.2 41.3  10.6
Circumferential strain (%) -21.8  3.4 -20.7  3.1 *
eGFR = estimated globular ﬁltration rate; LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; LVEF = left ventricular
ejection fraction; GLS = global longitudinal strain; Ssr = systolic strain rate;
* p0.05 compared with baseline value
https://doi.org/10.1371/journal.pone.0175544.t002
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Fig 4. Bullseyemap of GLS after anthracycline therapy. A. in the group with subclinical LV dysfunction
(reduction in GLS!11%) and B. in the group without subclinical LV dysfunction. * p0.05 compared to before
anthracycline therapy.
https://doi.org/10.1371/journal.pone.0175544.g004
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Diastolic parameters are listed in Table 4. Peak E velocity, E/A ratio, pulmonary vein dia-
stolic velocity, E’ velocity and early diastolic strain rate (Esr) were significantly reduced post
anthracycline therapy. Atrial fraction and late diastolic strain rate (Asr) increased post treat-
ment. Diastolic function grade was more prevalent with ‘impaired diastolic function’ increas-
ing from 46% to 57% (p<0.001) and normal diastolic function decreasing from 53% to 42%
(p<0.001). Fourteen percent (20/140) of patients had an increase in diastolic dysfunction
grade following anthracycline treatment. Patients with>11% reduction in systolic GLS had a
significant increase in diastolic dysfunction grade compared to those without changes in GLS
(30% vs. 11%; p = 0.04). Furthermore, there was a greater percentage change in early diastolic
strain rate (p<0.001), E velocity (p<0.001), and the E’ velocity (p = 0.007) in the group with
subclinical LV dysfunction compared to those without. Multivariate regression analysis of
these independent predictors (percentage change in early diastolic strain rate, E velocity and
the E’ velocity) demonstrated that the percentage change in early diastolic strain rate
(p = 0.004) and E velocity (p = 0.01) remained predictive of>11% reduction in systolic GLS.
Discussion
In the present study we evaluated LV systolic function prior to, and within seven days of com-
pleting anthracycline based chemotherapy using LVEF and strain analysis, in 140 consecutive
breast cancer patients. The principal findings of the study were; 1) longitudinal and circumfer-
ential strain were significantly reduced after anthracycline therapy, despite clinically insignifi-
cant changes in LVEF, 2) LV subclinical dysfunction, defined as a>11% reduction in GLS,
occurred in 22% of the cohort, 3) reductions in global strain were induced equally by doxoru-
bicin and epirubicin, 4) in patients with>11% reduction in GLS, greater segmental strain
reduction was evident and 5) increased occurrence of diastolic dysfunction occurred with sub-
clinical systolic dysfunction.
This study includes a relatively large number of breast cancer patients treated only with
anthracycline chemotherapy, and confirms the occurrence of subclinical LV systolic dysfunc-
tion post therapy as reported previously [11, 16, 17]. Anthracycline induced cardiotoxicity is
caused by multiple mechanisms [18] resulting in myocardial cell death and interstitial fibrosis
immediately after exposure and is dependent on the cumulative dose [10, 19]. A systematic
review reported that alterations in strain occurred prior to significant changes in LVEF [20],
and GLS was the most consistent measure, whilst LVEF had variability with clinically signifi-
cant reductions reported only at late follow up [20]. Within the current cohort, changes indica-
tive of LV subclinical dysfunction using GLS were observed in 22% of patients, whilst there
was no evidence of cardiotoxicity by LVEF. Our results provide additional evidence that
Table 3. Left atrial (LA) volumes.
Before anthracycline chemotherapy After anthracycline chemotherapy
LA maximum volume indexed (mL/m2) 27.1  6.2 26.9  5.9
LA minimum volume indexed (mL/m2) 12.2  3.6 12.3  3.3
Pre ’a’ wave volume indexed (mL/m2) 18.6  4.9 18.6  4.8
LA total emptying volume indexed (mL/m2) 14.7  4.2 14.6  3.6
LA total emptying fraction (%) 54  10 54  7
Conduit volume indexed (mL/m2) 15.3  6.0 15.8  6.1
Passive emptying volume indexed (mL/m2) 8.4  3.1 8.3  2.7
Passive emptying fraction (%) 32  8 31  8
Active emptying volume indexed (mL/m2) 6.3  2.1 6.3  2.5
Active emptying fraction (%) 34  7 34  7
https://doi.org/10.1371/journal.pone.0175544.t003
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changes in global LV function are associated with greater regional involvement. Anthracycline
cardiotoxicity may predominantly affect the subendocardial LV layer, which is primarily com-
posed of longitudinal fibres [18] as measured by GLS. LVEF is largely a measure of radial func-
tion; thus alterations in LVEF may not be apparent until substantial myocardial involvement
occurs.
Negishi et al demonstrated that a reduction of>11% in GLS was predictive of the longer
term reduction in LVEF and cardiotoxicity [14] in patients receiving trastuzumab and/or con-
current anthracyclines. In the current study, investigating only anthracycline therapy, 22% of
patients had a reduction in GLS by>11% [10]. A recent study reported that LV end diastolic
volume, LVEF and GLS measured post anthracycline treatment were independently associated
with the development of cardiotoxicity [21]. Furthermore, higher GLS (-17% vs -12%) at the
time of cardiotoxicity diagnosis was associated with subsequent improvement of LVEF [21].
Other studies have demonstrated that GLS was independently associated with all-cause mor-
tality [22], major adverse cardiovascular events [23] and cardiotoxicity [24]. Furthermore,
early reductions in LVEF and GLS after anthracycline chemotherapy persist at follow up [16,
25]. Longer term multicentre studies are required to determine the extent of early change that
best predicts future cardiotoxicity, in such patients.
Doxorubicin and epirubicin are the most frequently used anthracyclines in breast cancer
regimens [2]. Both agents are limited by dose-dependent cardiotoxicity, however the toxicity
profile of doxorubicin may be worse than epirubicin [2]. In the current cohort there were no
significant differences in LV function of both LVEF and GLS between patients receiving doxo-
rubicin and epirubicin, although the subgroups differed in size.
The incidence of myocardial damage after anthracycline chemotherapy may be enhanced
by smoking [26], preexisting cardiovascular disease, coexisting damage or individual patient
genetic predisposition [10, 18]. Development of subclinical LV dysfunction in the current
study was not associated with any cardiovascular risk factors or clinical parameters, specifically
Table 4. Left ventricular diastolic parameters.
Before anthracycline chemotherapy After anthracycline chemotherapy
Mitral inﬂow E Velocity (m/s) 0.68  0.14 0.64  0.13 *
A Velocity (m/s) 0.63  0.14 0.64  0.16
E/A ratio 1.13  0.32 1.04  0.29 *
Deceleration time (ms) 212  40 212  44
Atrial fraction (%) 36.0  7.0 39.6  8.5 *
Pulmonary vein ﬂow Systolic velocity (m/s) 0.50  0.14 0.49  0.16
Diastolic velocity (m/s) 0.41  0.12 0.38  0.12 *
Atrial reversal velocity (cm/s) 0.27  0.07 0.27  0.09
Tissue Doppler imaging E’ average velocity (cm/s) 9.1  2.4 8.4  2.6 *
E/E’ average ratio 7.6  2.3 7.7  2.5
A’ average velocity (cm/s) 9.0  2.4 9.1  2.2
LV diastolic grade Normal (%) 53 42 *
Impaired (%) 46 57 *
Pseudonormal (%) 1 1
Strain rate Esr (s-1) 1.54  0.23 1.48  0.23 *
E/Esr (s-1) 0.44  0.10 0.44  0.10
Asr (s-1) 0.98  0.24 1.04  0.22 *
* p0.05 compared with baseline value
Esr = early diastolic strain rate; Asr = late diastolic strain rate
https://doi.org/10.1371/journal.pone.0175544.t004
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anthracycline drug, dose, age and body habitus, thereby highlighting the mandate for regular
cardiac assessment in all patients receiving anthracyclines.
Early identification of subclinical LV dysfunction is important as this patient subgroup
requires close monitoring and enables early initiation of cardioprotective agents. Treatment
with an angiotensin receptor blocker (candesartan) prior to anthracycline, trastuzumab and
radiotherapy was demonstrated to alleviate reduced LVEF [27], in the PRADA trial, whilst
there was no advantage in metoprolol (beta blocker) [27], albeit in a small number of patients.
However, others have shown early implementation of beta blockers improved GLS in patients
with subclinical LV dysfunction receiving anthracyclines, trastuzumab or both [7]. Further-
more, Seicean et al reported in a large observational study that incidental and continuous inci-
dental beta blocker treatment reduced the onset of new heart failure in patients treated with
anthracyclines and trastuzumab [28]. An in-vitro mice study showed a link between the tyrosine
kinase receptor and beta adrenergic systems which may explain the treatment benefits of beta
blockers particularly in patients receiving trastuzumab (tyrosine kinase receptor antibody) [29].
In the current cohort, only few patients were receiving beta blocker or angiotensin converting
enzyme inhibitor before anthracycline therapy; no significant differences were observed imme-
diately after treatment. Further studies are needed to validate the cost effectiveness and benefits
of beta blockers, angiotensin converting enzyme inhibitors or a combination of agents adminis-
tered prior as indicated by subclinical LV dysfunction in preventing heart failure.
Diastolic dysfunction has been previously reported following anthracycline chemotherapy
[26, 30–33], albeit in small groups. The development of diastolic dysfunction has been
reported in up to 57% of patients treated with anthracycline chemotherapy and were indepen-
dently predicted by age and body mass index [31]. Furthermore, we have also previously
reported reduced early diastolic strain rate post anthracycline therapy [32].
LV diastolic grade was worse in the current cohort after anthracycline chemotherapy.
Importantly, diastolic dysfunction was more prevalent in the sub group with>11% reduction
in GLS, demonstrating the close association between systolic and diastolic function. In fact,
the only predictors of>11% reduction in GLS was early diastolic strain rate and the mitral
peak E velocity. Altered early LV relaxation resulted in augmented active atrial contraction
with increased atrial fraction and late diastolic strain rate, to compensate for the decreased vol-
ume transfer during early diastole. These changes, however, were only evident by Doppler
parameters and not atrial volume measurements, which are more reflective of the chronicity of
LV diastolic dysfunction. The monitoring of diastolic function is of particular importance as
alterations in diastolic function with relatively preserved systolic function can also result in
heart failure.
Limitations
This single-centre study (n = 140) is significantly larger than previous single-centre studies. Due
to cost constraints cardiac biomarkers could not be obtained in the majority of the cohort. The
study was limited by the short duration of patient follow-up, and therefore the longer term
impact of early reduction in GLS is uncertain; longer term follow up is ongoing to determine
the significance of these early observations. Another imaging modality may have provided addi-
tional information about LV systolic function; the use of MRI was beyond the scope of the cur-
rent study. 3D echocardiography, contrast imaging and stress testing were not performed in the
current cohort. Image acquisition and measurements were performed using equipment from a
single vendor (GE); therefore values are not comparable with non-GE machines [34]. Measure-
ment of GLS is limited by 2D image quality and temporal resolution. As reported, 11 patients
were excluded due to poor image quality following breast reconstruction.
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Conclusion
Subclinical LV dysfunction by GLS was observed in 22% of patients. There was an increase in
prevalence of LV diastolic dysfunction in the subgroup with>11% reduction in GLS. No clini-
cal risk factors were predictive of subclinical LV dysfunction, thus emphasizing the need for all
patients to be monitored for deterioration in both systolic and diastolic function following
anthracycline treatment. Longer term follow up is needed and is presently ongoing to deter-
mine the clinical importance of these early findings.
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